France Recombinant Plasma Protein Therapeutics Market Insight
France Recombinant Plasma Protein Therapeutics market size is growing at a 8.9% CAGR, driven by increasing incidence of rare genetic and blood disorders, rising adoption of recombinant biologics, expanding biotechnology innovation, and growing demand.
France Recombinant Plasma Protein Therapeutics Market Insights Forecasts to 2035
- The France Recombinant Plasma Protein Therapeutics Market Size Was Estimated at USD 693.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.9% from 2025 to 2035
- The France Recombinant Plasma Protein Therapeutics Market Size is Expected to Reach USD 1627.08 Million by 2035
Notable Insights for France Recombinant Plasma Protein Therapeutics Market
- The recombinant coagulation factors segment dominates the France recombinant plasma protein therapeutics market and generated approximately USD 310 million in revenue during 2025. Strong demand for advanced hemophilia therapies continues supporting segment expansion.
- The rare genetic disease treatment segment is expected to witness strong growth during the forecast period with an estimated CAGR of 9.5%, supported by increasing precision medicine adoption and biologics innovation.
- Approximately 45% of total market revenue in France is generated by recombinant coagulation factor therapies.
- Nearly 55% of therapeutic demand comes from hematology and rare disease treatment applications.
Download the eBook (ToC)
- Demand for recombinant biologics continues increasing due to improved safety and targeted treatment effectiveness.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Recombinant Plasma Protein Therapeutics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Recombinant Plasma Protein Therapeutics Market
- Novo Nordisk
- Takeda Pharmaceutical
- CSL Behring
- Pfizer
- Roche
- Sanofi
- Bayer
- BioMarin Pharmaceutical
- Grifols
- Octapharma
- Others
Recent Developments:
- In April 2026, Novo Nordisk expanded its recombinant hemophilia therapy portfolio with advanced long-acting coagulation factor treatments.
- In January 2026, Takeda Pharmaceutical strengthened its rare disease biologics pipeline targeting plasma protein deficiency disorders and immunological conditions.
Market Segmentation:
France Recombinant Plasma Protein Therapeutics Market, By Product Type
- Recombinant Coagulation Factors
- Recombinant Albumin
- Recombinant Immunoglobulins
- Others
France Recombinant Plasma Protein Therapeutics Market, By Application
- Hemophilia
- Immunodeficiency Disorders
- Thrombotic Disorders
- Rare Genetic Diseases
- Others
France Recombinant Plasma Protein Therapeutics Market, By End-User
- Hospitals
- Specialty Clinics
- Research Institutes
- Others
Expert Views:
The France recombinant plasma protein therapeutics market will expand steadily due to rising rare disease prevalence, biologics adoption, and recombinant protein engineering advancements. Next-generation hemophilia therapies, personalized medicine, expanded biotech research, and biologic treatment investments will drive future growth.